1. Home
  2. ULCC vs KALV Comparison

ULCC vs KALV Comparison

Compare ULCC & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Frontier Group Holdings Inc.

ULCC

Frontier Group Holdings Inc.

N/A

Current Price

$6.05

Market Cap

1.1B

ML Signal

N/A

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

N/A

Current Price

$26.98

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ULCC
KALV
Founded
1994
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
ULCC
KALV
Price
$6.05
$26.98
Analyst Decision
Hold
Strong Buy
Analyst Count
8
5
Target Price
$5.21
$32.60
AVG Volume (30 Days)
4.3M
2.9M
Earning Date
05-05-2026
07-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,724,000,000.00
$50,000,000.00
Revenue This Year
$23.76
$185.42
Revenue Next Year
$11.48
$59.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
495.66
52 Week Low
$3.02
$9.83
52 Week High
$6.66
$26.98

Technical Indicators

Market Signals
Indicator
ULCC
KALV
Relative Strength Index (RSI) 67.71 75.64
Support Level $4.69 $14.22
Resistance Level $6.10 N/A
Average True Range (ATR) 0.35 0.05
MACD 0.04 -0.25
Stochastic Oscillator 90.75 98.15

Price Performance

Historical Comparison
ULCC
KALV

About ULCC Frontier Group Holdings Inc.

Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos, and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. The majority of revenue is from Domestic flight follow by International.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: